<DOC>
	<DOC>NCT00264498</DOC>
	<brief_summary>The primary objective is to demonstrate in chemotherapy na√Øve patients with advanced (Stage IIIB or IV) NSCLC and ECOG PS 2 non-inferiority in progression free survival (PFS) for ZD1839 compared to gemcitabine/carboplatin.</brief_summary>
	<brief_title>Phase II Iressa &amp; Carbo/Gem in NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Advanced Non Small cell Lung Cell Lung cancer Never received chemotherapy Up and about 50% of waking hours Spread of lung cancer to the brain Low level of white blood cells Radiotherapy within 4 weeks Patients were entered to this study, initiated in 2004, before the significance of predictive factors such as smoking history, adenocarcinoma histology and mutation status was described.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Non-Small-Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>